Obesity in patients with HIV infection: epidemiology, consequences and treatment options

References

• Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117:214–220.
   PubMed Web of Science ®Google Scholar
• Pacheco AG, Tuboi SH, Faulhaber JC, et al. Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil. PLoS One. 2008;3:e1531.
   PubMed Web of Science ®Google Scholar
• Womack JA, Chang CC, So-Armah KA, et al. HIV infection and cardiovascular disease in women. J Am Heart Assoc. 2014;3:e001035.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Liese AD, Winniford MD, et al. Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol. 2014;37:517–522.
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–622.
   PubMed Web of Science ®Google Scholar
• Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171:737–743.
   PubMedGoogle Scholar
• Post WS, Budoff M, Kingsley L, et.al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160:458–467.
   PubMed Web of Science ®Google Scholar
• Idris NS, Grobbee DE, Burgner D, et al. Effects of paediatric HIV infection on childhood vasculature. Eur Heart J. 2016 Jan 7. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Di Cesare M, Bentham J, Stevens GA, et al. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387:1377–1396.
   PubMed Web of Science ®Google Scholar
• Mave V, Erlandson KM, Gupte N, et al.. Inflammation and change in body weight with antiretroviral therapy initiation in a multinational cohort of HIV-infected adults. J Infect Dis. 2016;214:65–72.
   PubMedGoogle Scholar
• Koethe JR, Jenkins CA, Lau B, et al.. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016;32:50–58.
   PubMed Web of Science ®Google Scholar
• Guehi C, Badjé A, Gabillard D, et al. High prevalence of being overweight and obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 temprano trial. AIDS Res Ther. 2016;13:12.
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Sharma S, Arastéh K, et al. Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(Suppl 1):46–54.
   PubMed Web of Science ®Google Scholar
• Pourcher G, Costagliola D, Martinez V. Obesity in HIV-infected patients in France: prevalence and surgical treatment options. J Visc Surg. 2015;152:33–37.
   PubMed Web of Science ®Google Scholar
• Semu H, Zack RM, Liu E, et al. Prevalence and risk factors for overweight and obesity among HIV-infected adults in Dar es Salaam, Tanzania. J Int Assoc Provid AIDS Care. 2014 Aug 21. Epub ahead of print.
   PubMedGoogle Scholar
• Míguez-Burbano MJ, Espinoza L, Cook RL, et al. Alcohol, brain derived neurotrophic factor and obesity among people living with HIV. J AIDS Clin Res. 2013;4:245.
   PubMedGoogle Scholar
• Hasse B, Iff M, Ledergerber B, et al. Obesity trends and body mass index changes after starting antiretroviral treatment: the Swiss HIV cohort study. Open Forum Infect Dis. 2014;1:ofu040.
   PubMedGoogle Scholar
• McCormick CL, Francis AM, Iliffe K, et al. Increasing obesity in treated female HIV patients from Sub-Saharan Africa: potential causes and possible targets for intervention. Front Immunol. 2014;5:507.
   PubMed Web of Science ®Google Scholar
• Thompson-Paul AM, Wei SC, Mattson CL, et al. Obesity among HIV-infected adults receiving medical care in the United States: data from the cross-sectional medical monitoring project and national health and nutrition examination survey. Medicine (Baltimore). 2015;94:e1081.
   PubMed Web of Science ®Google Scholar
• Freitas P, Carvalho D, Santos AC, et al. Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy. J Endocrinol Invest. 2012;35:964–970.
   PubMed Web of Science ®Google Scholar
• Nery MW, Martelli CM, Silveira EA, et al. Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. ScientificWorldJournal. 2013;2013:969281.
   PubMed Web of Science ®Google Scholar
• Falutz J, Rosenthall L, Kotler D, et al. Surrogate markers of visceral adipose tissue in treated HIV-infected patients: accuracy of waist circumference determination. HIV Med. 2014;15:98–107.
   PubMed Web of Science ®Google Scholar
• O’Neill T, Guaraldi G, Orlando G, et al. Combined use of waist and hip circumference to identify abdominally obese HIV-infected patients at increased health risk. PLoS One. 2013;8:e62538.
   PubMed Web of Science ®Google Scholar
• Arbeitman LE, O’Brien RC, Somarriba G, et al. Body mass index and waist circumference of HIV-infected youth in a Miami cohort: comparison to local and national cohorts. J Pediatr Gastroenterol Nutr. 2014;59:449–454.
   PubMed Web of Science ®Google Scholar
• Willig AL, Westfall AO, Overton ET, et al. Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults. AIDS Res Hum Retroviruses. 2015;31:898–904.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Liang Y, Garduño LS, et al. High risk of obesity and weight gain for HIV-infected uninsured minorities. J Acquir Immune Defic Syndr. 2014;65:e33–e40.
   PubMed Web of Science ®Google Scholar
• Buchacz K, Baker RK, Palella FJ Jr, et al.. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18:65–75.
   PubMed Web of Science ®Google Scholar
• Sirotin N, Hoover DR, Shi Q, et al. Food insecurity with hunger is associated with obesity among HIV-infected and at risk women in Bronx, NY. PLoS One. 2014;9:e105957.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Taejaroenkul S, Smeaton L, et al. A randomized comparison of anthropomorphic changes with preferred and alternative efavirenz-based antiretroviral regimens in diverse multinational settings. Open Forum Infect Dis. 2015;2:ofv095.
   PubMed Web of Science ®Google Scholar
• Sharma A, Bynum SA, Schneider MF, et al. Changes in body mass index following HAART initiation among HIV-infected women in the women’s interagency HIV study. J AIDS Clin Res. 2014;5.
   PubMedGoogle Scholar
• Lakey W, Yang LY, Yancy W, et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses. 2013;29:435–440.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Kitch D, Tierney C, et al. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS. 2013;27:2069–2079.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53:807–816.
   PubMed Web of Science ®Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29:256–265.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011;53:185–196.
   PubMed Web of Science ®Google Scholar
• Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012;26:475–481.
   PubMed Web of Science ®Google Scholar
• Lake JE, McComsey GA, Hulgan TM, et al. A randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012;26:532–540.
   PubMed Web of Science ®Google Scholar
• Ekali LG, Johnstone LK, Echouffo-Tcheugui JB, et al. Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in cameroonians receiving first-line antiretroviral treatment. Diabetes Metab. 2013;39:71–77.
   PubMed Web of Science ®Google Scholar
• Hendricks KM, Willis K, Houser R, et al. Obesity in HIV-infection: dietary correlates. J Am Coll Nutr. 2006;25:321–331.
   PubMed Web of Science ®Google Scholar
• Kruzich LA, Marquis GS, Wilson CM, et al. HIV-infected US youth are at high risk of obesity and poor diet quality: a challenge for improving short- and long-term health outcomes. J Am Diet Assoc. 2004;104:1554–1560.
   PubMedGoogle Scholar
• Duran AC, Almeida LB, Segurado AA, et al. Diet quality of persons living with HIV/AIDS on highly active antiretroviral therapy. J Hum Nutr Diet. 2008;21:346–350.
   PubMed Web of Science ®Google Scholar
• Tanaka LF, Latorre Mdo R, Silva AM, et al. [High prevalence of physical inactivity among adolescents living with HIV/AIDS]. Rev Paul Pediatr. 2015;33:327–332. [ Portuguese].
   PubMedGoogle Scholar
• Frantz JM, Murenzi A. The physical activity levels among people living with human immunodeficiency virus/acquired immunodeficiency syndrome receiving high active antiretroviral therapy in Rwanda. SAHARA J. 2013;10:113–118.
   PubMed Web of Science ®Google Scholar
• Pedersen KK, Pedersen M, Trøseid M, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr. 2013;64:425–433.
   PubMed Web of Science ®Google Scholar
• Viladés C, Escoté X, López-Dupla M, et al. Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS). J Antimicrob Chemother. 2014;69:1653–1659.
   PubMed Web of Science ®Google Scholar
• Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, et al. FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. BMC Med. 2014;12:198.
   PubMed Web of Science ®Google Scholar
• Egaña-Gorroño L, Martínez E, Pérez I, et al. Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults. J Antimicrob Chemother. 2014;69:3076–3084.
   PubMed Web of Science ®Google Scholar
• Koethe JR, Grome H, Jenkins CA, et al. The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. AIDS. 2016;30:83–91.
   PubMed Web of Science ®Google Scholar
• Hirigo AT, Tesfaye DY. Influences of gender in metabolic syndrome and its components among people living with HIV virus using antiretroviral treatment in Hawassa, southern Ethiopia. BMC Res Notes. 2016;9:145.
   PubMedGoogle Scholar
• Longo-Mbenza B, Apalata T, Longokolo M, et al. Association of helicobacter pylori infection with the metabolic syndrome among HIV-infected black Africans receiving highly active antiretroviral therapy. Cardiovasc J Afr. 2015;26:52–56.
   PubMed Web of Science ®Google Scholar
• Jarrett OD, Wanke CA, Ruthazer R, et al. Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus. AIDS Patient Care STDS. 2013;27:266–271.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Liese AD, Jerrell JM, et al. Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time. Diabet Med. 2014;31:1185–1193.
   PubMed Web of Science ®Google Scholar
• Tien PC, Schneider MF, Cox C, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012;61:334–340.
   PubMed Web of Science ®Google Scholar
• Capeau J, Bouteloup V, Katlama C, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26:303–314.
   PubMed Web of Science ®Google Scholar
• Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227–1234.
   PubMed Web of Science ®Google Scholar
• Herrin M, Tate JP, Akgün KM, et al. Weight gain and incident diabetes among HIV infected-veterans initiating antiretroviral therapy compared to uninfected individuals. J Acquir Immune Defic Syndr. 2016 May 9. Epub ahead of print.
   PubMedGoogle Scholar
• Pillay S, Aldous C, Mahomed F. A deadly combination - HIV and diabetes mellitus: where are we now? S Afr Med J. 2016;106:378–383.
   Google Scholar
• Stambullian M, Feliu MS, Cassetti LI, et al. Nutritional status and lipid profile in HIV-infected adults. Endocr Metab Immune Disord Drug Targets. 2015;15:302–307.
   PubMed Web of Science ®Google Scholar
• Asiki G, Murphy GA, Baisley K, et al. Prevalence of dyslipidaemia and associated risk factors in a rural population in South-Western Uganda: a community based survey. PLoS One. 2015;10:e0126166.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Jerrell JM, Liese AD, et al. Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011. Metab Syndr Relat Disord. 2013;11:417–426.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Yang OO, Kendall MA, et al. Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults. Lipids Health Dis. 2013;12:23.
   PubMed Web of Science ®Google Scholar
• Okello S, Kanyesigye M, Muyindike WR, et al. Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda. J Hypertens. 2015;33:2039–2045.
   PubMed Web of Science ®Google Scholar
• Antonello VS, Antonello IC, Grossmann TK, et al. Hypertension–an emerging cardiovascular risk factor in HIV infection. J Am Soc Hypertens. 2015;9:403–407.
   PubMed Web of Science ®Google Scholar
• Kagaruki GB, Mayige MT, Ngadaya ES, et al. Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions. BMC Public Health. 2014;14:904.
   PubMed Web of Science ®Google Scholar
• De SGV, Ricci E, Maggi P, et al. Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. Am J Hypertens. 2014;27:222–228.
   PubMed Web of Science ®Google Scholar
• Ogunmola OJ, Oladosu OY, Olamoyegun AM. Association of hypertension and obesity with HIV and antiretroviral therapy in a rural tertiary health center in Nigeria: a cross-sectional cohort study. Vasc Health Risk Manag. 2014;10:129–137.
   PubMedGoogle Scholar
• Srinivasa S, Fitch KV, Wong K, et al. RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients. J Clin Endocrinol Metab. 2015;100:2873–2882.
   PubMed Web of Science ®Google Scholar
• Isasti G, Pérez I, Moreno T, et al. Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses. 2013;29:20–24.
   PubMed Web of Science ®Google Scholar
• Hulgan T, Boger MS, Liao DH, et al. Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. Mediators Inflamm. 2014;2014:1–10.
   Web of Science ®Google Scholar
• Conley LJ, Bush TJ, Rupert AW, et al. Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapy. AIDS. 2015;29:2201–2207.
   PubMed Web of Science ®Google Scholar
• Bryant AK, Fazeli PL, Letendre SL, et al. Complement component 3 is associated with metabolic comorbidities in older HIV-positive adults. AIDS Res Hum Retroviruses. 2016;32:271–278.
   PubMed Web of Science ®Google Scholar
• Langkilde A, Petersen J, Henriksen JH, et al. Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls. Immun Ageing. 2015;12:9.
   PubMed Web of Science ®Google Scholar
• Parfieniuk-Kowerda A, Czaban SL, Grzeszczuk A, et al. Assessment of serum IGF-1 and adipokines related to metabolic dysfunction in HIV-infected adults. Cytokine. 2013;64:97–102.
   PubMed Web of Science ®Google Scholar
• Goswami U, Baker JV, Wang Q, et al. Sleep apnea symptoms as a predictor of fatigue in an urban HIV clinic. AIDS Patient Care STDS. 2015;29:591–596.
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Akgün KM, Fiellin DA, et al. Prevalence and correlates of obstructive sleep apnoea among patients with and without HIV infection. HIV Med. 2015;16:105–113.
   PubMed Web of Science ®Google Scholar
• Morse CG, McLaughlin M, Matthews L, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-,monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis. 2015;60:1569–1578.
   PubMed Web of Science ®Google Scholar
• Nishijima T, Gatanaga H, Shimbo T, et al. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection. PLoS One. 2014;9:e87596.
   PubMed Web of Science ®Google Scholar
• Kotler DP, He Q, Engelson ES, et al. The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial. Antivir Ther. 2016;21:107–116.
   PubMedGoogle Scholar
• Price JC, Seaberg EC, Latanich R, et al. Risk factors for fatty liver in the multicenter AIDS Cohort Study. Am J Gastroenterol. 2014;109:695–704.
   PubMed Web of Science ®Google Scholar
• Fr S, He J, Letendre S, et al. Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation. J Acquir Immune Defic Syndr. 2015;68:281–288.
   PubMed Web of Science ®Google Scholar
• McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012;78:485–492.
   PubMed Web of Science ®Google Scholar
• Archibald SL, McCutchan JA, Sanders C, et al. Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. J Neurovirol. 2014;20:603–611.
   PubMed Web of Science ®Google Scholar
• Canuto JM, Canuto VM, De Lima MH, et al. Risk factors associated with hypovitaminosis D in HIV/aids-infected adults. Arch Endocrinol Metab. 2015;59:34–41.
   PubMed Web of Science ®Google Scholar
• Pinnetti C, Federico L, Lorenzini P, et al. Relationship between body mass index and bone mineral density in HIV-infected patients referred for DXA. J Int AIDS Soc. 2014;17(4 Suppl 3):19569.
   PubMedGoogle Scholar
• Somarriba G, Lopez-Mitnik G, Ludwig DA, et al. Physical fitness in children infected with the human immunodeficiency virus: associations with highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2013;29:112–120.
   PubMed Web of Science ®Google Scholar
• Shah K, Hilton TN, Myers L, et al. A new frailty syndrome: central obesity and frailty in older adults with the human immunodeficiency virus. J Am Geriatr Soc. 2012;60:545–549.
   PubMed Web of Science ®Google Scholar
• Koethe JR, Jenkins CA, Turner M, et al. Body mass index and the risk of incident noncommunicable diseases after starting antiretroviral therapy. HIV Med. 2015;16:67–72.
   PubMed Web of Science ®Google Scholar
• Albuquerque VM, Zírpoli JC, De Barros Miranda-Filho D, et al. Risk factors for subclinical atherosclerosis in HIV-infected patients under and over 40 years: a case-control study. BMC Infect Dis. 2013;13:274.
   PubMed Web of Science ®Google Scholar
• Orlando G, Guaraldi G, Zona S, et al. Ectopic fat is linked to prior cardiovascular events in men with HIV. J Acquir Immune Defic Syndr. 2012;59:494–497.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Westfall AO, Chamot E, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr. 2012;61:600–605.
   PubMed Web of Science ®Google Scholar
• Sharma A, Hoover DR, Shi Q, et al. Relationship between body mass index and mortality in HIV-infected HAART users in the women’s interagency HIV study. PLoS One. 2015;10:e0143740.
   Google Scholar
• Ning S, Xue Z, Wei J, et al. [HIV/AIDS related mortality in southern Shanxi province and its risk factors]. Zhonghua Liu Xing Bing Xue Za Zhi. 2015;36:245–249. [ Chinese].
   PubMedGoogle Scholar
• Scherzer R, Heymsfield SB, Lee D, et al. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS. 2011;25:1405–1414.
   PubMed Web of Science ®Google Scholar
• Jones CY, Hogan JW, Snyder B, et al. Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. Clin Infect Dis. 2003;37(Suppl 2):S69–S80.
   PubMed Web of Science ®Google Scholar
• Boodram B, Plankey MW, Cox C, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the women’s interagency HIV study. AIDS Patient Care STDS. 2009;23:1009–1016.
   PubMed Web of Science ®Google Scholar
• Shor-Posner G, Campa A, Zhang G, et al. When obesity is desirable: a longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort. J Acquir Immune Defic Syndr. 2000;23:81–88.
   PubMed Web of Science ®Google Scholar
• Martinez SS, Campa A, Bussmann H, et al. Effect of BMI and fat mass on HIV disease progression in HIV-infected, antiretroviral treatment-naïve adults in Botswana. Br J Nutr. 2016;115:2114–2121.
   PubMed Web of Science ®Google Scholar
• Koethe JR, Jenkins CA, Lau B, et al. Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America,1998-2010. HIV Med. 2015;16:572–577.
   PubMed Web of Science ®Google Scholar
• Johnson KD, Cai B, Duffus W, et al. Longitudinal association between BMI at diagnosis and HIV disease progression. AIDS Behav. 2014;18:2249–2257.
   PubMed Web of Science ®Google Scholar
• Koethe JR, Jenkins CA, Lau B, et al. Higher time-updated body mass index: association with improved CD4+ cell recovery on HIV treatment. J Acquir Immune Defic Syndr. 2016 Apr 21;1. Epub ahead of print.
   PubMedGoogle Scholar
• Blashill AJ, Mayer KH, Crane HM, et al. Body mass index, immune status, and virological control in HIV-infected men who have sex with men. J Int Assoc Provid AIDS Care. 2013;12:319–324.
   PubMedGoogle Scholar
• Marzolini C, Sabin C, Raffi F, et al. Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS. 2015;29:193–200.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Roediger M, Eberly LE, et al. Impact of weight on immune cell counts among HIV-infected persons. Clin Vaccine Immunol. 2011;18:940–946.
   PubMed Web of Science ®Google Scholar
• Damouche A, Lazure T, Avettand-Fènoël V, et al. Adipose tissue is a neglected viral reservoir and an inflammatory site during chronic HIV and SIV infection. PLoS Pathog. 2015;11:e1005153.
   PubMed Web of Science ®Google Scholar
• Couturier J, Suliburk JW, Brown JM, et al. Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. AIDS. 2015;29:667–674.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043–2050.
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207–215.
   PubMed Web of Science ®Google Scholar
• Fitch K, Abbara S, Lee H, et al. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS. 2012;26:587–597.
   PubMed Web of Science ®Google Scholar
• Lazzaretti RK, Kuhmmer R, Sprinz E, et al. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial. J Am Coll Cardiol. 2012;59:979–988.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Poulia KA, Yannakoulia M, et al. Adherence to mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism. 2009;58:854–859.
   PubMed Web of Science ®Google Scholar
• Fillipas S, Cherry CL, Cicuttini F, et al. The effects of exercise training on metabolic and morphological outcomes for people living with HIV: a systematic review of randomised controlled trials. HIV Clin Trials. 2010;11:270–282.
   PubMed Web of Science ®Google Scholar
• Ogalha C, Luz E, Sampaio E, et al. A randomized, clinical trial to evaluate the impact of regular physical activity on the quality of life, body morphology and metabolic parameters of patients with AIDS in Salvador, Brazil. J Acquir Immune Defic Syndr. 2011;57(Suppl 3):S179–S185.
   PubMed Web of Science ®Google Scholar
• Yarasheski KE, Cade WT, Overton ET, et al. Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Am J Physiol Endocrinol Metab. 2011;300:E243–E251.
   PubMed Web of Science ®Google Scholar
• Engelson ES, Agin D, Kenya S, et al. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism. 2006;55:1327–1336.
   PubMed Web of Science ®Google Scholar
• Cutrono SE, Lewis JE, Perry A, et al. The effect of a community-based exercise program on inflammation, metabolic risk, and fitness levels among persons living with HIV/AIDS. AIDS Behav. 2016;20:1123–1131.
   PubMed Web of Science ®Google Scholar
• Fitch KV, Anderson EJ, Hubbard JL, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS. 2006;20:1843–1850.
   PubMed Web of Science ®Google Scholar
• Petróczi A, Hawkins K, Jones G, et al. HIV patient characteristics that affect adherence to exercise programmes: an observational study. Open AIDS J. 2010;4:148–155.
   PubMedGoogle Scholar
• Kent SJ. Loss of control of HIV viremia associated with the fat malabsorption drug orlistat. AIDS Res Hum Retroviruses. 2012;28:961–962.
   PubMedGoogle Scholar
• Gervasoni C, Cattaneo D, Di Cristo V, et al. Orlistat: weight lost at cost of HIV rebound. J Antimicrob Chemother. 2016;71:1739–1741.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
   PubMed Web of Science ®Google Scholar
• Diamant M, van Agtmael M. Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes. Diabetes Care. 2012;35:e34.
   PubMedGoogle Scholar
• García de Lucas MD, Olalla Sierra J, Piña Fernández J. Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome. Diabetes Metab. 2015;41:102–103.
   PubMed Web of Science ®Google Scholar
• Sheffield CA, Kane MP, Busch RS. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. Pharmacotherapy. 2007;27:1449–1455.
   PubMed Web of Science ®Google Scholar
• Oriot P, Hermans MP, Selvais P, et al. Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. Ann Endocrinol (Paris). 2011;72:244–246.
   PubMed Web of Science ®Google Scholar
• Diehl LA, Fabris BA, Barbosa DS, et al. Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy. AIDS Patient Care STDS. 2008;22:779–786.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Yang Y, Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 2007;21:47–57.
   PubMed Web of Science ®Google Scholar
• Leung V, Chiu YL, Kotler DP, et al. Effect of recombinant human growth hormone and rosiglitazone for HIV-associated abdominal fat accumulation on adiponectin and other markers of inflammation. HIV Clin Trials. 2016;17:55–62.
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Albu J, Chiu YL, et al. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. PLoS One. 2013;8:e61160.
   PubMed Web of Science ®Google Scholar
• Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA. 2008;300:509–519.
   PubMed Web of Science ®Google Scholar
• Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:239–252.
   PubMed Web of Science ®Google Scholar
• Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359–2370.
   PubMed Web of Science ®Google Scholar
• Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95:4291–4304.
   PubMed Web of Science ®Google Scholar
• Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54:1642–1651.
   PubMed Web of Science ®Google Scholar
• Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312:380–389.
   PubMed Web of Science ®Google Scholar
• Alfa-Wali M, Seechurn S, Ayodeji O, et al. Outcomes of bariatric surgery in HIV-positive individuals. Minerva Chir. 2016;71:233–238.
   PubMedGoogle Scholar
• Zivich S, Cauterucci M, Allen S, et al. Long-term virologic outcomes following bariatric surgery in patients with HIV. Obes Res Clin Pract. 2015;9:633–635.
   PubMed Web of Science ®Google Scholar
• Fysekidis M, Cohen R, Bekheit M, et al. Sleeve gastrectomy is a safe and efficient procedure in HIV patients with morbid obesity: a case series with results in weight loss, comorbidity evolution, CD4 count, and viral load. Obes Surg. 2015;25:229–233.
   PubMed Web of Science ®Google Scholar